Expert Interview
A Third Look: Discussing intermediate-risk (IR) and high-risk (HR) non-muscle invasive bladder cancer (NMIBC)
Ticker(s): URGN, CGON, TARA, JNJ, ENGNAn Expert in Urologic Oncology.
Roughly how many patients with NMIBC do you currently manage?
Added By: max_adminOn a scale from 1- 10 how would you rate your level of excitement for TARA-002?
Added By: max_adminDo you expect community practices to see the logistics/cold-chain/thawing time/infection risk mitigation etc as hurdles for adoption of the virus-based agents?
Added By: max_adminWhat are your thoughts on the re-induction protocol introduced by TARA?
Added By: max_adminPresuming UGN-102 is approved for recurrent disease, what is your outlook on its adoption by community and academic practices?
Added By: max_adminHow sensitive are you to complete response performance as they vary among therapies? How do you regard CR and its durability in the context of the individual candidates' advantages and disadvantages?
Added By: max_adminAs a corollary to Q6, how do you expect these factors to play into your thinking on how to sequence the emerging options, given high recurrence rates?
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- May 21, 2025
- Call Time
- 05:00 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
